Bone Status in Obese, Non-diabetic, Antipsychotic-Treated Patients, and Effects of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide on Bone Turnover Markers and Bone Mineral Density

Background: Low bone mineral density (BMD) may constitute an underestimated comorbidity in schizophrenia patients undergoing long-term antipsychotic treatment. Glucagon-like peptide 1 (GLP-1) receptor agonists are antidiabetic drugs, which may also affect bone turnover. Methods: In planned secondary...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Front Psychiatry
Prif Awduron: Eriksson, Robert, Broberg, Brian V., Ishøy, Pelle L., Bak, Nikolaj, Andersen, Ulrik B., Jørgensen, Niklas R., Knop, Filip K., Ebdrup, Bjørn H.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Frontiers Media S.A. 2019
Pynciau:
Psychiatry
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6360839/
https://ncbi.nlm.nih.gov/pubmed/30745885
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fpsyt.2018.00781
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg